Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A Rybicki

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Blood|July 21, 2011
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737Sayer Al-Harbi, Brian T Hill, Suparna Mazumder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2009
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junctionDavid J Adelstein, Thomas W Rice, Lisa A Rybicki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancerCristina P Rodriguez, David J Adelstein, Thomas W Rice, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 20, 2012
Intramucosal esophageal adenocarcinoma: primum non nocereZhigang Li, Thomas W Rice, Xiuli Liu, et al.
Head & Neck|August 16, 2008
Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapyCristina P Rodriguez, David J Adelstein, Lisa A Rybicki, et al.
Human Pathology|August 13, 2015
Risk factor analysis of recurrence in low-grade endometrial adenocarcinomaAndres A Roma, Lisa A Rybicki, Denise Barbuto, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 2, 2002
Stage III non-small cell lung cancer and metachronous brain metastasesNader Moazami, Thomas W Rice, Lisa A Rybicki, et al.
Radiation Oncology (London, England)|July 11, 2013
Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomesTrevor J Bledsoe, Anisha R Noble, Grant K Hunter, et al.
American Journal of Clinical Oncology|April 7, 2007
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneityDavid J Adelstein, Thomas W Rice, Lisa A Rybicki, et al.
Annals of Human Genetics|January 12, 2010
Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndromeMaren Sullivan, Zoran Erlic, Michael M Hoffmann, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Blood|July 21, 2011
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737Sayer Al-Harbi, Brian T Hill, Suparna Mazumder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2009
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junctionDavid J Adelstein, Thomas W Rice, Lisa A Rybicki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancerCristina P Rodriguez, David J Adelstein, Thomas W Rice, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 20, 2012
Intramucosal esophageal adenocarcinoma: primum non nocereZhigang Li, Thomas W Rice, Xiuli Liu, et al.
Head & Neck|August 16, 2008
Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapyCristina P Rodriguez, David J Adelstein, Lisa A Rybicki, et al.
Human Pathology|August 13, 2015
Risk factor analysis of recurrence in low-grade endometrial adenocarcinomaAndres A Roma, Lisa A Rybicki, Denise Barbuto, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 2, 2002
Stage III non-small cell lung cancer and metachronous brain metastasesNader Moazami, Thomas W Rice, Lisa A Rybicki, et al.
Radiation Oncology (London, England)|July 11, 2013
Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomesTrevor J Bledsoe, Anisha R Noble, Grant K Hunter, et al.
American Journal of Clinical Oncology|April 7, 2007
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneityDavid J Adelstein, Thomas W Rice, Lisa A Rybicki, et al.
Annals of Human Genetics|January 12, 2010
Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndromeMaren Sullivan, Zoran Erlic, Michael M Hoffmann, et al.
Pageof 11